ArticleJournal for immunotherapy of cancer2024

Oral PD-L1 inhibitor GS-4224 selectively engages PD-L1 high cells and elicits pharmacodynamic responses in patients with advanced solid tumors.

Jared M Odegard et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.